康宁杰瑞制药与石药集团合作开发的新药联合疗法上市申请已获受理

财中社08-18 18:31

8月18日，康宁杰瑞制药（09966）发布公告，公司与石药集团（01093）附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛一线治疗不可切除或转移性人类表皮生长因子受体2阳性成人乳腺癌的新药上市申请已获受理，并纳入优先审评审批程序。　　本次新药上市申请主要是基于一项关键III期临床研究。研究结果显示，安尼妥单抗和HB1801联合疗法一线治疗HER2+晚期乳腺癌的无进展生存期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2660246906?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-18 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660246906","market":"sh","top_or_hot":-1,"title":"康宁杰瑞制药与石药集团合作开发的新药联合疗法上市申请已获受理","media":"财中社","content":"<div>\n<p>8月18日，康宁杰瑞制药（09966）发布公告，公司与石药集团（01093）附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛一线治疗不可切除或转移性人类表皮生长因子受体2阳性成人乳腺癌的新药上市申请已获受理，并纳入优先审评审批程序。　　本次新药上市申请主要是基于一项关键III期临床研究。研究结果显示，安尼妥单抗和HB1801联合疗法一线治疗HER2+晚期乳腺癌的无进展生存期...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608183844683914.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康宁杰瑞制药与石药集团合作开发的新药联合疗法上市申请已获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康宁杰瑞制药与石药集团合作开发的新药联合疗法上市申请已获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 18:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202608183844683914.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月18日，康宁杰瑞制药（09966）发布公告，公司与石药集团（01093）附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛一线治疗不可切除或转移性人类表皮生长因子受体2阳性成人乳腺癌的新药上市申请已获受理，并纳入优先审评审批程序。　　本次新药上市申请主要是基于一项关键III期临床研究。研究结果显示，安尼妥单抗和HB1801联合疗法一线治疗HER2+晚期乳腺癌的无进展生存期...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608183844683914.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202608183844683914.html","article_id":"2660246906","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844683914.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660246906","pubTimestamp":1787049060,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"8月18日，康宁杰瑞制药（09966）发布公告，公司与石药集团（01093）附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛一线治疗不可切除或转移性人类表皮生长因子受体2阳性成人乳腺癌的新药上市申请已获受理，并纳入优先审评审批程序。本次新药上市申请主要是基于一项关键III期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1515":"抗疫概念","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","01093":"石药集团","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","IPOS":"Renaissance International IPO ETF","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","BK1521":"挪威政府全球养老基金持仓","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","09966":"康宁杰瑞制药-B","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1191":"制药","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","BK1161":"生物科技","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","BK1574":"生物医药B类股","IE0008368742.USD":"首域中国增长基金I Acc"},"translate_title":"The application for the listing of new drug combination therapy jointly developed by Alphamab and CSPC has been accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"IPOS":1.5,"KURE":0.6,"09966":1.5},"content_text":"8月18日，康宁杰瑞制药（09966）发布公告，公司与石药集团（01093）附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛一线治疗不可切除或转移性人类表皮生长因子受体2阳性成人乳腺癌的新药上市申请已获受理，并纳入优先审评审批程序。　　本次新药上市申请主要是基于一项关键III期临床研究。研究结果显示，安尼妥单抗和HB1801联合疗法一线治疗HER2+晚期乳腺癌的无进展生存期，优于现行标准治疗曲妥珠单抗联合帕妥珠单抗和多西他赛。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660246906","isCrawlerRequest":true}